Photo by charlesdeluvio from unsplash
Eptacog beta is a new recombinant activated human factor VII bypassing agent approved in the United States for the treatment and control of bleeding in patients with haemophilia A or… Click to show full abstract
Eptacog beta is a new recombinant activated human factor VII bypassing agent approved in the United States for the treatment and control of bleeding in patients with haemophilia A or B with inhibitors 12 years of age or older.
Keywords:
haemophilia inhibitors;
eptacog beta;
control bleeding;
treatment control
Journal Title: Haemophilia
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Haemophilia
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!